Product Description
Cethromycin, a new ketolide, has a similar mechanism of action to telithromycin with an apparently better safety profile. Cethromycin displays in vitro activity against selected gram-positive, gram-negative, and atypical bacteria. Cethromycin appears to be a promising ketolide for the treatment of mild to moderate community-acquired pneumonia. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/23463743/)
Mechanisms of Action: Bacterial Growth Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Advanced Life Sciences
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Pneumonia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CL05-001 | P3 |
Completed |
Pneumonia |
2007-10-01 |
2019-03-21 |
Treatments |
|
| 2006-002110-35 | P3 |
Completed |
Pneumonia |
2007-05-09 |
2022-03-13 |
Treatments |
|
| CL06-001 | P3 |
Completed |
Pneumonia |
2007-05-01 |
2019-03-21 |
Treatments |